News

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.

At SLEEP 2025, Fung shared that masked taper plus CBT-I led to higher benzodiazepine discontinuation and improved sleep in older adults.

Mortality from ALD rose significantly across most demographic groups in the US from 1999 to 2022, especially during and following the COVID-19 pandemic onset.

In the second part of a 2-part episode, hosts Kimberly Brown and Nancy Reau break down 3 more notable abstracts from the 2025 EASL Congress.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.

At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.

A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.

HCPLive spoke with Bowles at SLEEP 2025 on the staggered schedule, referred to as 1/3/2/3, and how it impacts firefighters' sleep.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.

If approved, mavorixafor will be the second FDA-approved treatment and the first oral medication for CN.

This interview with Peter Lio, MD, at RAD 2025 provides several insights into the topic of topical steroid withdrawal versus atopic dermatitis and what the distinction may be.

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

FDA approves the new therapy under the name Enflonsia, offering effective RSV prevention for infants during their first RSV season.

In this interview at RAD 2025, Peter Lio, MD, highlighted whether precision medicine is a possibility in the near future in the atopic dermatitis management space.

In this Q&A discussion, Glick highlights several important points about topical steroid withdrawal and atopic dermatitis.

Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.

A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

This study highlights rates among females with up to 6 years of upadacitinib use of major adverse cardiovascular events, VTE, and malignancy.

A recent study reveals how personality traits like neuroticism and extraversion influence bedtime procrastination in young adults, impacting sleep health.